Robeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Robeco Institutional Asset Management B.V. reduced its holdings in Alnylam Pharmaceuticals by 6.9% in the second quarter, owning 96,368 shares valued at approximately $31.4 million after selling 7,113 shares during the quarter.
• Alnylam recently benefited from favorable analyst upgrades, with target prices raised by multiple firms, including Needham & Company to $478 and The Goldman Sachs Group to $566, as part of a broader consensus rating of "Moderate Buy."
• In late August, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam stock, resulting in a 12.01% decrease in her ownership position, signaling possible insider selling amidst overall strong market performance and institutional interest.

Robeco Institutional Asset Management B.V. trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,368 shares of the biopharmaceutical company's stock after selling 7,113 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.07% of Alnylam Pharmaceuticals worth $31,425,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ALNY. SVB Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter worth about $27,000. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares in the last quarter. Washington Trust Advisors Inc. grew its position in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares in the last quarter. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 77.7% during the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 87 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its position in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 175 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Needham & Company LLC upped their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Piper Sandler upped their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. The Goldman Sachs Group upped their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a report on Tuesday, September 16th. Finally, Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $439.58.

Alnylam Pharmaceuticals Trading Down 1.0%

NASDAQ ALNY opened at $456.35 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a 50-day moving average of $441.57 and a 200-day moving average of $338.75. The firm has a market cap of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares of the company's stock, valued at $29,568,138.45. This represents a 12.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares of the company's stock, valued at $7,561,800. The trade was a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock worth $44,160,261 over the last three months. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.